Fundraising Fox

Mable

AcquiredYC S21

London, GB · Founded 2019 · 7 employees · 7 known investors

Find your way into Mable

1,268 people in our graph share verified history with the Mable team — schools, employers, funds. One of them is your warm intro.

Mariaunlockedknows Inna Thalmann · together at University of Oxford (overlapped)
×2knows the team · via University of Oxford
×6knows the team · via Y Combinator
knows the team · via Breega
knows the team · via University of Regensburg
knows the team · via The American University of Paris

Mable is a genomics-based telehealth platform that provides personalized migraine care by analyzing patients' genetic and biomarker data to inform individualized treatment plans. The company serves migraine sufferers seeking precision medicine alternatives to traditional trial-and-error medication approaches.

Also known as DiveHealth · Neurolytic Healthcare · Neurolytic Healthcare Ltd.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesHealth TechTelehealthGenomicsUnited KingdomUnited States of AmericaEuropeAmerica / CanadaFully Remote

Founders & leadership· Y Combinator alumni (S21)

Mable was founded in 2019 by Roman Rothaermel, Inna Thalmann, Chris Eijsbouts, and Kumeren Govnder.

RRRoman Rothaermel
Roman RothaermelinFounderRoman Rothaermel holds an MSc in Biology from Tübingen University and an MSc in Neuroscience from Oxford University, where he also completed his PhD studying memory encoding and brain synchronization mechanisms. He has conducted research in neuropharmacology and drug target characterization.
ITInna Thalmann
Inna ThalmanninFounderInna Thalmann is co-founder and chief operating officer of Mable, a precision medicine company applying genomic sequencing to clinical decision-making. She holds a PhD in Econometrics with a health economics focus from the University of Oxford and completed postdoctoral research on phenotype algorithms for clinical trial design.
CEChris Eijsbouts
Chris EijsboutsinFounder
KG
Kumeren Govnder

Investors · 7

Initialized Capital✓ verifiedSan Francisco · $1M – $5M
Underscore VCBoston
VenrockPalo Alto · $500K – $10M
Y CombinatorSan Francisco · $500K
Arkitekt VenturesreportedNew York · $100K – $10M
First In VenturesreportedMiddletown · $50K – $200K

Also in the syndicate · 1

Illuminalead

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Crypto News. July 17, 2026 - by Crypto Integratedcryptointegrat.com · Jul 2026Multicoin Capital makes first Hyperliquid ecosystem investment in Trasia, an Asia-focused trading platform | The Blocktheblock.co · Jul 2026Mable raises $3M for DNA-based migraine treatmentaxios.com · Jul 2022Telehealth Startup Mable Raises $3.2M Seed | DealFlow's Healthcare Services Investment Newshealthcareservicesinvestmentnews.com · Jul 2022Introducing Mable. Revolutionizing Migraine Care, through the Power of DNA.trymable.com · Jul 2022Mable Raises $3M in Seed Funding - FinSMEsfinsmes.com · Oct 2019

Frequently asked questions

What does Mable do?
Mable is a genomics-based telehealth platform that provides personalized migraine care by analyzing patients' genetic and biomarker data to inform individualized treatment plans. The company serves migraine sufferers seeking precision medicine alternatives to traditional trial-and-error medication approaches.
Who founded Mable?
Mable was founded by Roman Rothaermel, Inna Thalmann, Chris Eijsbouts, Kumeren Govnder in 2019.
Who are Mable's investors?
Mable's investors include Initialized Capital, Underscore VC, Venrock, Y Combinator, Arkitekt Ventures, First In Ventures.
Where is Mable headquartered?
Mable is headquartered in London, GB.